MedPath

Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder

Not Applicable
Completed
Conditions
Anxiety Disorders
Opioid-use Disorder
Depressive Disorder
Interventions
Behavioral: Smartphone-Based Digital Intervention
Registration Number
NCT05047627
Lead Sponsor
Trustees of Dartmouth College
Brief Summary

The majority of opioid users meet criteria for anxiety and depressive disorders, but most substance use disorder treatment programs do not offer treatment for co-occurring mental health problems. Anxiety and depression may also be directly linked to opioid use itself. Although treatments have been developed for anxiety and depressive symptoms for opioid users within face-to-face settings, few treatment facilities offer these in-person interventions due to their high cost and time burden. Given the deficits in research on treatments for anxiety and depression among those with opioid use disorder, the current research will examine the efficacy of a digital intervention designed to treat anxiety and depressive symptoms by augmenting the state of the science medication-based opioid use disorder treatment. Over the course of the proposed study, the research team will design and test the feasibility and acceptability of a standalone mobile intervention designed to treat persons receiving medication treatment for opioid use disorder. Participants receiving medication treatment for opioid use disorder will be randomized to receive a digital intervention to treat anxiety and depression or care as usual for a total of four weeks. The overarching goal of the proposed work is to test the feasibility and acceptability of the proposed mobile intervention. The Investigators will also explore the preliminary efficacy by examining reductions in anxiety and depressive symptoms and opioid cravings and use. This work could lead to a low-cost scalable solution to augment gold-standard treatment as usual in opioid use disorder by decreasing levels of comorbidity of anxiety and depressive disorders, thereby ultimately improving the outcomes of opioid use disorder itself.

Detailed Description

The study team will recruit a population of 60 adults who are receiving medication treatment for OUD from an online study based on Google Adwords, Reddit, and Facebook advertisements as online recruitment has been shown to be a viable and cost-effective recruitment method for opioid users. The total sample size may be expanded if recruitment costs are lower than expected.

Participants will complete self-report assessments on their anxiety symptoms, depressive symptoms, opioid cravings, and opioid use behaviors. Participants will be randomized to a smartphone-based digital intervention or waitlist control condition. The digital intervention will be designed to treat participants' anxiety and depressive symptoms, and participants will be asked to use the intervention four times per week for four weeks (16 digital sessions).The smartphone intervention will also collect passive sensing data continuously during the 4 week period. Participants will complete post measures and one-month follow-up measures on anxiety symptoms, depressive symptoms, opioid cravings, and opioid use behaviors. The urine drug screen will be mailed to participants. Participants will also be asked to complete five urine tests to detect substance use (amphetamines, barbiturates, benzodiazepines, cocaine, ecstasy, marijuana, methamphetamine, opioids, oxycodone, and pcp) across the study (1 at pre-digital intervention, 1 during the digital intervention, 1 post-digital intervention, 1 between post and follow-up of the digital intervention, and 1 at the 1-month follow-up of the digital intervention). Participants will be instructed when to complete each urine test and will be asked to take a photo of the back the label of each test showing the results to the experimenters and to text these photos to a Google Voice Number maintained by the experimenters.

Thus, this proposal seeks to address a crucial deficit in the availability of treatments for anxiety and depressive disorders among persons with OUD to ultimately augment treatment for OUD.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
63
Inclusion Criteria
  • Adults (age 18 or older)
  • fluent in English
  • able to provide informed consent
  • meet current criteria for OUD (as defined by a Rapid Opioid Dependence Screen)
  • are receiving methadone, buprenorphine, and/or naltrexone for OUD
  • meet current criteria for an anxiety and/or depressive disorder (based on the Patient Health Questionnaire and the Generalized Anxiety Disorder Questionnaire).
Exclusion Criteria
  • active suicidality
  • psychosis
  • bipolar disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Smartphone Digital Intervention GroupSmartphone-Based Digital InterventionThe Smartphone Digital Intervention Group is the experimental group. Participants randomized to this group will download the smartphone intervention and be asked to use the intervention four times per week for four weeks ( 16 digital sessions). The smartphone digital intervention will also continuously collect passive sensing data. The smartphone digital intervention will be designed to treat anxiety and depression by providing informational videos to help participants treat these symptoms. These videos include information about physical activity, muscle relaxation, and other proven helpful interventions to help with anxiety and depression.
Primary Outcome Measures
NameTimeMethod
Change in anxiety symptoms as assessed by Generalized Anxiety Disorder- Q-IV Scale8 weeks from enrollment

Assesses anxiety symptoms. Possible GAD-Q-IV scores range from 0 to 12, with higher scores representing greater GAD symptom severity

Positive Test for Opioids8 weeks after enrollment

urine tests will detect substance use in participants

Change in depressive symptoms as assessed by Patient Health Questionnaire-98 weeks from enrollment

Assesses depressive symptoms, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day)

Secondary Outcome Measures
NameTimeMethod
Difficulties in emotion regulation using the Modified Difficulties in Emotion Regulation Scale (DERS)8 weeks after enrollment

Measures difficulties in emotion regulation with 21 items and a 5 point Likert scale (1 almost never - 5 almost always)

Estimates of Activities56 days (or 8-weeks)

Use mobile sensor and phone utilization data to develop individualized estimates of activities.

Estimates of Light Exposure56 days (or 8-weeks)

Use mobile sensor and phone utilization data to develop individualized estimates of light exposure.

Opioid Dependency using the Rapid Opioid Dependence Screenat baseline, up to 3 days after enrollment

The RODS is an eight-item questionnaire inquiring about tolerance; withdrawal; unintended dosage or duration of use; persistent desire and unsuccessful quit attempts; time spent obtaining using and recovering from opioid use.

Opioid Dependency using the Opioid Craving Scaleat baseline, up to 3 days after enrollment

The Opioid Craving Scale measures opioid cravings using three questions: (1) "How much do you currently crave opiates" (0 Not at all - 10 Extremely).

Self Regulation Scale8 weeks after enrollment

12-item momentary self-regulation scale that can capture self-regulatory dynamics at a momentary level using a 5 point scale (1 not at all- 5 extremely)

Estimates of sociability56 days (or 8-weeks)

Use mobile sensor and phone utilization data to develop individualized estimates of sociability

Trial Locations

Locations (1)

Center For Technology and Behavioral Health

đŸ‡ºđŸ‡¸

Lebanon, New Hampshire, United States

© Copyright 2025. All Rights Reserved by MedPath